



- (51) **International Patent Classification:**
C07H 5/06 (2006.01) C07H 13/04 (2006.01)
C07H 5/08 (2006.01)
- (21) **International Application Number:**
PCT/US2017/024908
- (22) **International Filing Date:**
30 March 2017 (30.03.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/315,144 30 March 2016 (30.03.2016) US
- (71) **Applicant:** AYUVIS RESEARCH LLC [US/US]; 1120 South Freeway, Fort Worth, TX 76104 (US).
- (72) **Inventors:** ACHARYA, Suchismita; 2302 Grizzly Run Lane, Euless, TX 76039 (US). PANDA, Santosh, K.; 335 West Side Dr, #203, Gaithersburg, MD 20878 (US). DAS, Pragnya; 1250 Providence Road, #95B, Secane, PA (US). BEAMON, Agarwal; 1250 Providence Road, #95B, Secane, PA (US).
- (74) **Agent:** FOSTER, David, C.; Roberts Foster LLP, 1400 Civic Place, Suite 221, Southlake, TX 76092 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** NOVEL COMPOSITIONS AND THERAPEUTIC METHODS

Fig. 1



(57) **Abstract:** The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and/or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel diseases (IBD), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and/or any disorder associated with inflammation, immunomodulation and microbial infection.

WO 2017/173024 A1

NOVEL COMPOSITIONS AND THERAPEUTIC METHODS**By**

Suchismita Acharya, Eules, Texas, USA

Santosh K Panda, Gaithersburg, MD, USA

Pragnya Das, Pennsylvania, PA

Beamon Agarwal, Pennsylvania, PA

CROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 62/315144 filed March 30, 2016, which application is incorporated herein by reference.

TECHNICAL FIELD OF THE INVENTION

[0002] The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and/or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel diseases (IBD), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and/or any disorder associated with inflammation, immunomodulation and microbial infection.

BACKGROUND OF THE INVENTION

[0003] Sepsis was identified as one of the five conditions that account for the most expensive hospital stays in the United States. The outcome of sepsis is particularly unfavorable in elderly, immunocompromised, and critically ill patients. Besides its clinical challenge, the treatment of sepsis imposes a large economic burden on healthcare systems worldwide. With an estimated >900,000 cases occurring in the United States alone each year, the annual total costs have been estimated to be approximately \$26 billion nationally. Currently, one of three broad adjunctive (nonantibiotic) therapy approaches are typically used to treat sepsis: (1) improving supportive care (i.e. oxygenation/ventilation strategies, optimization of fluid/vasopressor use, early goal-

directed therapy); (2) targeting bacterial virulence factors (i.e. antiendotoxin antibodies, endotoxin removal columns); and (3) targeting host response factors (i.e. corticosteroids, anticytokine drugs, anticoagulants). However, current therapies are not completely effective in patients with sepsis and septic shock. These therapies are even less effective in immunocompromised and older patients.

BRIEF SUMMARY OF THE INVENTION

[0004] The present invention overcomes the drawbacks of the prior art by providing small molecular weight, water soluble, oligosaccharides (compounds **1-3**) that exhibit antagonist activity against TLR4 useful for treating inflammatory disorders, such as age-related macular degeneration (AMD) pathogenesis. Such inflammatory conditions include, but are not limited to, ocular inflammatory diseases and choroidal neovascularization. Specifically, the present invention relates to compounds (**4, 15, 16 and 25**) for the treatment of inflammation. In some embodiments the inflammation may be caused by polymicrobial infections. In some embodiments the compounds find use in the treatment of sepsis and severe sepsis, SIRS and septic shock.

[0005] Compounds of the present invention have been unexpectedly found to possess superior anti-inflammatory activity in inhibiting inflammatory biomarkers such as TNF- α , IL-1 β and IL-6 in LPS induced human monocyte assay and producing anti-inflammatory cytokine IL-10 in monocytes. Compounds of present invention protected mice from both lethal gram negative sepsis against *Escherichia Coli* and polymicrobial sepsis in a cecal ligation and puncture model. Accordingly, the present disclosure provides methods of inhibiting inflammatory biomarkers such as, but not limited to, TNF- α , IL-1 β and IL-6 in LPS induced human monocyte assay by administering the compounds disclosed herein to a patient in need thereof. In addition the present disclosure provides methods of protecting mice from lethal gram negative sepsis against *Escherichia coli* by administering the compounds disclosed herein to a patient in need thereof. Compounds of the present invention have also been unexpectedly found to possess broad spectrum antimicrobial activity against both gram positive (methicillin susceptible *Staphylococcus aureus* and methicillin resistant *Staphylococcus aureus*), gram negative (*E. Coli*, *P. Aeruginosa*, *A. Baumannii*, *K. Pneumonia*) bacteria as well as fungus (*C. Albicans*) mostly found in burn and septic wounds. Accordingly, the present disclosure provides methods of

treating infection caused by both gram positive (methicillin susceptible *Staphylococcus aureus* and methicillin resistant *Staphylococcus aureus*), gram negative (*E. Coli*, *P. Aeruginosa*, *A. Baumannii*, *K. Pneumonia*) bacteria as well as fungus (*C. Albicans*) by administering compounds disclosed herein to a patient in need thereof. Compounds of the present invention have also been unexpectedly found to inhibit and eradicate biofilm formed by *S. Aureus*. Accordingly, the present disclosure provides methods of inhibiting or eradicating biofilm formed by a microorganism, such as but not limited to *S. Aureus* by contacting a surface with compounds disclosed herein. Compounds of present invention also demonstrated superior *in vivo* efficacy in protecting mice against cecal ligation and puncture (CLP) induced death and organ dysfunction. Compounds of the present invention have also been unexpectedly found to possess superior activity against HMGB1 induced inflammation in mouse macrophages and reduced VEGF expression in retinal pigmental epithelial cells (ARPE-19) and daily intraperitoneal injection of the compound was able to reduce the average size of CNV lesions to about 60% of those in control mice treated with vehicle only. Accordingly, the disclosure provides methods of protecting a subject in need thereof from infection or disorders associated with infection by treating said subject with a compound as disclosed herein.

[0006] The foregoing brief summary broadly describes the features and technical advantages of certain embodiments of the present invention. Additional features and technical advantages will be described in the detailed description of the invention that follows. Novel features which are believed to be characteristic of the invention will be better understood from the detailed description of the invention when considered in connection with any accompanying figures. However, figures provided herein are intended to help illustrate the invention or assist with developing an understanding of the invention, and are not intended to be definitions of the invention's scope.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0008] **FIG. 1** is a graph showing the results of an evaluation of the TLR4 antagonist compound **1** of the present invention in a mouse endotoxemia sepsis model and illustrates that compound **1** protected mice from lethal gram negative sepsis against *E. Coli*.

[0009] **FIG. 2** is a graph showing the results of an evaluation of the TLR4 antagonist compound **4** of the present invention in a cecal ligation and puncture (CLP) model and illustrates that compound **4** protected mice from CLP induced polymicrobial sepsis and death.

[0010] **FIG. 3** is the histopathology of major organs which demonstrates that, on treatment of compound **4**, a compound of present invention reversed the major pathological changes and tissues resembled to sham group.

[0011] **FIG. 4** demonstrated that compound **4** of present invention effectively down regulates the inflammatory cytokines in vivo in CLP mice.

[0012] **FIG. 5** is graphs showing the results of an evaluation of the compound **15** and **25** of the present invention in a cecal ligation and puncture (CLP) model and illustrates that both compounds protected mice from CLP induced polymicrobial sepsis and death.

[0013] **FIG. 6** demonstrates that an evaluation of the TLR4 antagonist compound **2** of the present invention in a laser induced CNV mouse model for wet AMD. Compound **2** decreased the choroidal neovascularization ~60% as compared to the positive control.

[0014] **FIG. 7** demonstrates that a series of compounds of present invention binds to TLR4 receptor effectively and not to TLR2 receptor.

[0015] **FIG. 8 (A-B)** demonstrates that compounds of present invention inhibited LPS induced production of inflammatory mediators in human monocytes.

[0016] **FIG. 9** demonstrates that compounds of present invention inhibits HMGB1 induced production of inflammatory mediator (TNF- α) in mouse bone marrow derived macrophages.

[0017] **FIG. 10** demonstrates that compounds of present invention inhibits HMGB1 induced production of inflammatory mediators (TNF- α , i-NOS) and upregulate M2 biomarker CXCR4 in mouse macrophages.

[0018] **FIG 11** demonstrates that compounds of present invention produce anti-inflammatory cytokine IL-10.

[0019] **FIG 12** demonstrates that compounds of present invention (**1**, and **2**) decreased HMGB1 induced VEGF production in ARPE-19 cell.

[00020] FIG. 13 demonstrates that compounds of present invention have broad-spectrum antimicrobial activity.

[00021] FIG. 14 demonstrates that compounds of present invention inhibited biofilm formation.

[00022] FIG. 15 demonstrates that the broad-spectrum antimicrobial activity of the compounds of present invention is via disruption of cell membrane.

[00023] FIG. 16 demonstrates that compounds of present invention don't bind to the plasma serum protein.

[00024] FIG. 17 demonstrates that compounds of present invention are not toxic to fibroblast cells.

[00025] FIG. 18 shows the synthetic scheme for preparing compound 11.

[00026] FIG. 19 provides the synthetic scheme for preparing compounds 22-23.

[00027] FIG. 20 provides the synthetic scheme for preparing compounds 24-25.

DETAILED DESCRIPTION OF THE INVENTION

[00028] In sepsis caused by gram-negative bacteria, lipopolysachharide (LPS) activates the immune system through signaling receptor Toll Like Receptor 4 (TLR4) to initiate the process for production of inflammatory cytokines (TNF- α , IL-1 β , IL-6, ROS) responsible for hyper-inflammation. Thus, some investigators are seeking to develop antagonists that block either activation through TLRs or downstream signaling pathways that inhibit the storm of inflammatory molecules. However, no target molecule has progressed beyond experimental and preclinical work, except Eritoran, a LPS analog which failed in clinical trial with possible reason of poor clinical study design [Opal et al, JAMA, 309, 1154-1162 (2013)]. The underlying mechanism of action for most other class of compounds is not completely understood [Leon, et al., Pharm. Res. 25(8):1751-1761 (2008); Athina and Thierry, Frontiers in Immunology 4387 (2013)].

[00029] The compounds of present innovation are small molecules that can synergistically inhibit inflammation microbial infection and upregulate M2 biomarker such as IL-10 with therapeutic potential to treat sepsis, septicemia and septic shock.


[00030] Posterior segment neovascular ocular diseases, as exemplified by proliferative diabetic retinopathy (PDR), exudative age-related macular degeneration (AMD) and retinopathy of prematurity (ROP), are a growing and huge health threat which require new effective therapies. Retinal neovascularization associated with PDR is the leading cause of blindness in working age adults. Choroidal neovascularization (CNV) is responsible for 200,000 new cases of exudative AMD each year in the US rendering this neovascular pathology the leading cause of legal blindness in non-third world nations. The projected number of people with AMD in 2020 is 196 million, increasing to 288 million in 2040 [Wong et al, *The Lancet Global Health* **2014**, 2, e106-e116]. Pathological angiogenesis associated with ROP is the major cause of blindness in children under the age of seven [Harrell et al, *Neonatal Network* **2007**, 26, 371-378].

[00031] Multiple lines of evidence suggest that Toll Like Receptor (TLR4) signaling may be associated with pathologic changes in retinal diseases [Cho et al, *Investigative Ophthalmology & Visual Science* **2009**, 50, 5614-5618], including AMD eyes by oxidized lipids, lipofuscin and by drusen components. Once activated, TLR4 could contribute to the pathogenesis of AMD by multiple mechanisms such as release of TNF- α , interleukin-1 β , and other pro-inflammatory mediators. TLR4 activation suppresses Wnt signaling, leading to reduced growth factor expression, secretion, and increased photoreceptor death in response to oxidative stress as well as can also lead to oxidative damage of photoreceptor outer segments. TLR4 has a direct effect on several inflammation-related signaling pathways including MAPK, NF κ - β and Jak1/Stat1 and shown to mediate neuronal toxicity through caspase-3, neuronal iNOS and ERK1/2, JNK1/2 and p38. Interestingly, TLR4-mediated microglial activation by endogenous photoreceptor proteins in retinal inflammation can aggravate retinal cell death. Finally, release of high-mobility group box-1 in ischemic neural tissue has been shown to initiate TLR4-dependent responses that contribute to retinal neovascularization [He et al, *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2013;33:330-338].

[00032] Accordingly, there exists a need for more effective treatments for inflammation and in particular for both dry and wet AMD pathogenesis. The compounds and methods described herein, therefore demonstrated that inhibition of TLR4 activity is of therapeutic value in AMD and other retinal diseases. The compounds of present innovation are small molecules that can synergistically inhibit angiogenesis, inflammation and accelerate phagocytosis with therapeutic potential to treat AMD.

[00033] Prior to the present disclosure, however, it does not appear that there are any reports published on the use of chitohexaose (compound **1**), chitoheptaose (compound **2**) and chitooctaose (compound **3**) and derivatives thereof as TLR4 antagonist for inhibiting inflammation and angiogenesis for ocular indications such as dry/wet AMD, diabetic retinopathy, or any chronic ocular inflammation.

[00034] In one embodiment, the principles of the present disclosure provide a compound of Formula (**I**):



Formula I

where:

R = H, C(O)R₁, alkyl, benzyl, substituted benzyl

R₁ = CH₃, alkyl, piperidine nitroxyl

R₂ = H, C(O)R¹ or

aceloxy alkyl carbamate of the following formula

R₂ = C(O)OCHR₃OC(O)OR₄, piperidine nitroxyl

R₃ = H, CH₃, C₂H₅, Isopropyl


R₄ = optimally substituted alkyl group

X = O, NH, S

R₅ = alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl, heteroalkyl, heterocycloalkyl, piperidine nitroxyl, piperidine N-hydroxylamine

n = 0-7

[00035] In another embodiment, the present disclosure provides a compound of Formula (**II**):




Formula II


where:

a. $n = 2-7$


[00036] Additional compounds of the present disclosure include the following structures shown below:




1




2




3



26



27




28

[00037] Compounds of the present disclosure (2, 3) have shown unexpectedly potent activity in inhibiting LPS and HMGB1 induced inflammation biomarkers (TNF- α , IL-1 β and IL-6) in bone derived mouse macrophages as well as in human monocytes. Compounds 1 and 2 decrease the production of VEGF in ARPE-19 cells. Compound 2 showed significant decrease in

CNV size in lased induced mice model for wet AMD. Compounds of the present invention (1-3) can be synthesized using the synthesis schemes illustrated in FIG. 19 in conjunction with knowledge available in the prior art and may be modified as needed:

[00038] In another embodiment, the present invention provides a compound of Formula (III):



[002] **Formula III**


where:

$n = 0-5$

$R = COR_1$

$R_1 = CH_3, \text{ alkyl,}$


[00039] Additional compounds of the present invention include the following structures shown below:



[00040] Compounds of the present invention (4) have shown unexpectedly superior activity in inhibiting LPS induced inflammation biomarkers (TNF- α , IL-1 β and IL-6) in human monocytes. As illustrated in Figs. 2-4, Compound 4 demonstrated high efficacy in protecting organ dysfunction and death of mice in a cecal ligation and puncture (CLP) model of sepsis at 10mg/kg on intravenous (IV) dosing and downregulated inflammatory cytokines such as TNF- α , IL-1 β and IL-6 in a statistically significant manner.

[00041] Compounds of the present invention (4-6) can be synthesized using reported procedure as describe in Mohamed R. E et al, Carbohydrate research, 2001, 331, 129-142.

[00042] In another embodiment, the present invention provides a compound of Formula (IV):



1. **Formula IV**


where:

R = H and C(O)R¹


R¹ = piperidine nitroxyl or piperidine N-hydroxyl amine

n = 0-7


[00043] Additional compounds of the present invention include the following structures shown below:



7




8



[00044] Compounds of the present invention (**11**) have shown unexpectedly superior activity in inhibiting LPS induced inflammation biomarkers (TNF- α , IL-1 β and IL-6) in human monocytes. Accordingly, the compounds find use as anti-inflammatory compounds.

Compounds of the present invention (**7-11**) can be synthesized using the synthesis schemes illustrated in FIG. 18 in conjunction with knowledge available in the art.

[00045] In another embodiment, the present invention provides a compound of Formula (V):



where:


$n = 0-5$

$R = \text{H}, \text{C}(\text{O})\text{CH}_3, \text{C}(\text{O})\text{-piperidine nitroso}, \text{C}(\text{O})\text{-piperidine N-hydroxyl}$


$R_1 = \text{alkyl}, \text{cycloalkyl}, \text{aryl}, \text{substituted aryl}, \text{heteroaryl}, \text{piperidine nitroso}, \text{piperidine N-}$

hydroxyl

[00046] Additional compounds of the present invention include the following structures shown below:



[00047] Compounds of the present invention (12-25) have shown to inhibit LPS induced inflammation biomarkers (TNF- α , IL-1 β and IL-6) in human monocytes and upregulated anti-inflammatory cytokine, M2 biomarker IL-10. Compound 12 also showed broad spectrum antimicrobial activity against gram negative, gram positive bacteria as well fungus. Compound 12 unexpectedly inhibited biofilm formation by MSSA and MRSA. Compound 25 demonstrated high survival, organ protection in CLP mice model of sepsis when administered intravenously (10mg/kg dose). Accordingly, compounds as described herein find use as anti-inflammatory molecules in some embodiments. In some embodiments the compounds are anti-infective or antimicrobial.



Formula-VI

[003]

where:


n = 0-1

R = benzyl, substituted benzyl

R₁ = COCH₃, N-dimethylmaleimide

R₃ = cyclohexyl, p-nitro phenyl, piperidine nitroso, piperidine-N-hydroxyl, p-methoxy phenyl.

[0048] Additional compounds of the present invention include the following structures shown below:



[00049] Compounds of the present invention have shown to inhibit LPS induced inflammation biomarkers (TNF- α , IL-1 β and IL-6) in human monocytes and upregulated IL-10. Compounds **15** also showed broad spectrum antimicrobial activity against gram negative, gram positive bacteria as well fungus. Compounds **15** unexpectedly inhibited biofilm inhibition by MSSA and MRSA. Compound **15** demonstrated high survival, organ protection in CLP mice model of sepsis when administered intravenously (5.0 mg/kg dose). Compounds of the present invention can be synthesized using the synthesis schemes illustrated in FIG. 19 developed by us in conjunction with knowledge available in the art.

[00050] Furthermore, certain embodiments comprise pharmaceutically acceptable salts of compounds according to the present invention. Pharmaceutically acceptable salts comprise, but are not limited to, soluble or dispersible forms of compounds according to the present invention that are suitable for treatment of disease without undue undesirable effects such as allergic reactions or toxicity. Representative pharmaceutically acceptable salts include, but are not limited to, acid addition salts such as acetate, citrate, benzoate, lactate, or phosphate and basic addition salts such as lithium, sodium, potassium, or aluminum.

FORMULATIONS

[00051] In some embodiments, the compounds of the present disclosure are incorporated into parenteral formulations. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, and intra-arterial injections with a variety of infusion techniques. Intra-arterial and intravenous injection as used herein includes administration through catheters. Preferred for certain indications are methods of administration that allow rapid access to the tissue or organ being treated, such as intravenous injections for the treatment of endotoxemia or sepsis.

[00052] The compounds of the present disclosure will be administered in dosages which will provide suitable inhibition of LPS activation of target cells; generally, these dosages are, preferably between 50-3000 mg/patient, or from 100-2500 mg/patient or from 200-2000 mg/patient or from 500-1000 mg/patient or from 750-1000 mg/patient, more preferably, between 500-750 mg/patient and most preferably, between 250-500 mg/patient. The dosages are preferably once a day for 28 days, more preferably twice a day for 14 days or most preferably 3 times a day for 7days.

[00053] Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration.

[00054] Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension may also contain one or more preservative such as ethyl or n-propyl p-hydroxybenzoate.

[00055] The pharmaceutical compositions of the invention are preferably in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenteral-acceptable diluent or solvent, such as a solution in 1,3-butanediol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.

[00056] In some embodiments the formulation comprises PLA or PLGA microparticles and may be further mixed with Na_2HPO_4 , hydroxypropyl methylcellulose, polysorbate 80, sodium chloride, and/or edentate disodium.

[00057] Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending

agents and thickening agents. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders of the kind previously described.

[00058] It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, and sex of the individual being treated; the time and route of administration; the rate of excretion; other drugs which have previously been administered; and the severity of the particular disease undergoing therapy.

[00059] In some embodiments the compositions of the present disclosure also contain from about 80% to about 99.5%, preferably from about 90 or 95% to about 98.5% of a compatible non-aqueous pharmaceutically acceptable topical vehicle. Some vehicles are described in US Patent 4,621,075, which is incorporated herein for this disclosure. Although it is preferred that these vehicles be free of water, the compositions of the present invention may contain up to about 5% water without significant adverse effects on the formation of the desired gels. These non-aqueous vehicle components are also well-known in the pharmaceutical arts, and they include (but are not limited to) short chain alcohols and ketones and emollients, such as hydrocarbon oils and waxes, lanolin and lanolin derivatives, silicone oils, monoglyceride, diglyceride, and triglyceride esters, fatty alcohols, alkyl and alkenyl esters of fatty acids, alkyl and alkenyl diesters of dicarboxylic acids, polyhydric alcohols and their ether and ester derivatives; wax esters and beeswax derivatives. Preferred vehicles incorporate methanol, ethanol, n-propanol, isopropanol, butanol, polypropylene glycol, polyethylene glycol and mixtures of these components. Particularly preferred vehicles include ethanol, n-propanol and butanol, especially ethanol. These preferred solvents may also be combined with other components, such as diisopropyl sebacate, isopropyl myristate, methyl laurate, silicone, glycerine and mixtures of these components, to provide non-aqueous vehicles which are also useful in the present invention. Of these additional components, diisopropyl sebacate is especially useful. In fact, preferred vehicles include mixtures of ethanol and diisopropyl sebacate in ratios, by weight, of from about 4:1 to about 1:4. Preferred vehicles contain from about 15% to about 35% diisopropyl sebacate and from about 65% to about 85% ethanol.

[00060] Compositions of the present invention may additionally contain, at their art-established usage levels, compatible adjunct components conventionally used in the formulation of topical pharmaceutical compositions. These adjunct components may include, but are not limited to, pharmaceutically-active materials (such as supplementary antimicrobial or anti-inflammatory ingredients, e.g., steroids) or ingredients used to enhance the formulation itself (such as excipients, dyes, perfumes, skin penetration enhancers, stabilizers, preservatives, and antioxidants). Since the compositions of the present invention permit the formation of gels without requiring the presence of conventional gelling agents, such agents are preferably not included. Examples of such agents include the pharmaceutically-acceptable acidic carboxy polymers, such as the Carbopol compounds commercially available from B. F. Goodrich Chemicals, Cleveland, Ohio.

[00061] The gel-form compositions of the present invention may be formulated by the conventional mixing of the components described above. Gel formation takes place within from about 2 minutes to about 16 hours after mixing, depending upon the components utilized.

[00062] In one embodiment the cream, lotion or gel packaged in a common trigger spray container will be firmly adhered to the area of interest as a regular cream does after it is sprayed out from the container. This is described in WO 98/51273, which is incorporated herein by reference. Accordingly, in one aspect, the present disclosure provides a pharmaceutical non-aerosol spray composition for topical application, which comprises the compounds as described herein alone or in combination. The compounds are present in an amount in the range of 0.1% to 20% or in some embodiments from 1 to 15% by weight, or in some embodiments from 2 to 10% by weight of cream, lotion or gel. The compounds used in the present invention can be incorporated into a neutral hydrophilic matrix cream, lotion or gel. In a first preferred embodiment, the cream or lotion matrix for topical application is characterized by polyoxyethylene alkyl ethers. In a second preferred embodiment, the gel is characterized by high molecular weight polymer of cross-linked acrylic acid. Polyoxyethylene alkyl ethers are non-ionic surfactants widely used in pharmaceutical topical formulations and cosmetics primarily as emulsifying agents for water-in-oil and oil-in-water emulsions. It is characterized in this invention as a base for non-aerosol trigger sprayable cream or lotion. Cross-linked acrylic acid polymer (Carbomer) employed to form the gel is another object of this invention.

[00063] A particularly suitable base for non-aerosol spray is therefore a cream or lotion containing from 1 to 25% of polyoxyethylene alkyl ethers, 3 to 40% of humectant and 0.1 to 1% of preservative or preservatives and the balance to 100% being purified water. Aptly the polyoxyethylene alkyl ether can be one or any combination selected from the group consisting of polyoxyl 20 cetostearyl ether (Atlas G-3713), poloxyl 2 cetyl ether (ceteth-2), poloxyl 10 cetyl ether (ceteth-10), poloxyl 20 cetyl ether (ceteth-20), poloxyl 4 lauryl cetyl ether (laureth-4), poloxyl 23 lauryl cetyl ether (laureth-23), poloxyl 2 oleyl ether (oleth-2), poloxyl 10 oleyl ether (oleth-10), poloxyl 20 oleyl ether (oleth-20), poloxyl 2 stearyl ether (steareth-2), poloxyl 10 stearyl ether (steareth-10), poloxyl 20 stearyl ether (steareth-20) and poloxyl 100 stearyl ether (steareth-100). Suitable humectant can be one or any combination selected from the group consisting of propylene glycol, polyethylene glycol, sorbitol or glycerine. Suitable preservative is one or any combination selected from the group consisting of methylparaben, propylparaben, benzyl alcohol, benzoic acid, sodium benzoate, sorbic acid and its salt or phenylethyl alcohol.

[00064] Another suitable base for non-aerosol spray is a gel containing from 0.1 to 2.0% of Carbomer, 0.1 to 1% of alkaline solution, 3 to 40% of humectant and 0.1 to 1% of preservative or preservative as and the balance to 100% being purified water. Aptly the Carbomer can be one or any combination selected from the group consisting of Carbomer 934, Carbomer 940 or Carbomer 941. The suitable humectant, preservative and purified water for the gel are same as that in the case or cream or lotion. Other sprayable formulations are described in US Pre-Grant Publication US2005/00255048, which is expressly incorporated herein by reference.

Ophthalmic formulation (topical and intravitreal dosing):

[00065] The compound of the invention will typically be a small percentage of the total ophthalmic composition. The compound of the invention will typically be at least 0.01 w/v %, more typically at least 0.1 w/v % and even more typically at least 0.5 w/v % of the ophthalmic composition. The compound of the invention will also typically be no greater than 5.0 w/v %, even more typically no greater than 3.0 w/v % and even more typically no greater than 1.5 w/v % of the ophthalmic composition.

[00066] The ophthalmic composition will also typically include a suitable ophthalmic vehicle for delivery of the compound to the eye. It is contemplated that the ophthalmic

composition may be configured for topical or intravitreal application to the eye and the ophthalmic vehicle will likely be different depending upon the manner of application. Generally, for either topical or intravitreal applications, it is preferable that the ophthalmic composition be aqueous and include a substantial amount of water. Typically the composition will include at least 30 w/v %, more typically at least 80 w/v % and even more typically at least 90 w/v % water (e.g., purified water).

[00067] For intravitreal applications, particularly when the ophthalmic composition is applied to the eye with a syringe, the ophthalmic compositions may include only or consist essentially of water and compound of the invention. For sustained drug release, PLGA or PLA macroparticle formulation of the compound of invention will be used as described by Shelke et al [Drug Deliv Transl Res. 2011, (1): 76–90]. Of course the ophthalmic composition could include other ingredients as well such as Na₂HPO₄, hydroxypropyl methylcellulose, polysorbate 80, sodium chloride, and edentate disodium.

[00068] It could also be the case that the vehicle be only or consist essentially of water for a topical application, particularly if that topical application is performed shortly after water is combined with the test compound or the composition is packaged in a manner to prevent contamination. However, if the ophthalmic composition is to be applied as a multi-dose ophthalmic composition over an extended period of time (e.g., as drops from an eye-dropper once, twice, thrice or more per day for multiple days), the ophthalmic composition will likely include additional ingredients such as antimicrobial or preservative agents or systems, surfactants, buffering agents, tonicity agents, anti-oxidants, viscosity-modifying agents any combinations thereof or the like.

[00069] For topical application, the compositions of the present invention typically include antimicrobial agent. Potential antimicrobial agents include, without limitation, hydrogen peroxide, chlorine containing preservatives such as benzalkonium chloride or others. According to a preferred aspect, however, the composition of the present invention is entirely or substantially free of any non-polymeric quaternary anti-microbial agents such as benzalkonium chloride (BAK). Most preferred antimicrobial agent in the pharmaceutical composition includes polymeric quaternary ammonium compound.

[00070] As used herein, the phrase “substantially free of” as it refers to an ingredient of the ophthalmic composition means that it is contemplated that the ophthalmic composition can

be either entirely devoid of that particular ingredient or includes only a nominal amount of that particular ingredient.

[00071] The polymeric quaternary ammonium compounds useful in the compositions of the present invention are those which have an antimicrobial effect and which are ophthalmically acceptable. Preferred compounds of this type are described in U.S. Pat. Nos. 3,931,319; 4,027,020; 4,407,791; 4,525,346; 4,836,986; 5,037,647 and 5,300,287; and PCT application WO 91/09523 (Dziabo et al.), which are expressly incorporated herein by reference. The most preferred polymeric ammonium compound is polyquaternium 1, otherwise known as POLYQUAD™ or ONAMERM™ with a number average molecular weight between 2,000 to 30,000. Preferably, the number average molecular weight is between 3,000 to 14,000.

[00072] The polymeric quaternary ammonium compounds are generally used in the suspensions of the present invention in an amount that is greater than about 0.00001 w/v %, more typically greater than about 0.0003 w/v % and even more typically greater than about 0.0007 w/v % of the suspension. Moreover, the polymeric quaternary ammonium compounds are generally used in the compositions of the present invention in an amount that is less than about 3 w/v %, more typically less than about 0.003 w/v % and even more typically less than about 0.0015 w/v % of the composition.

[00073] The antimicrobial agent of the composition of the present invention can additionally or alternatively include an antimicrobial system such as a borate/polyol complex system. As used herein, the term "borate" shall refer to boric acid, salts of boric acid, borate derivatives and other pharmaceutically acceptable borates, or combinations thereof. Most suitable are: boric acid, sodium borate, potassium borate, calcium borate, magnesium borate, manganese borate, and other such borate salts. Borate interacts with polyols, such as glycerol, propylene glycol, sorbitol and mannitol, to form borate polyol complexes. The type and ratio of such complexes depends on the number of OH groups of a polyol on adjacent carbon atoms that are not in trans configuration relative to each other. It shall be understood that weight/volume percentages of the ingredients polyol and borate include those amounts whether as part of a complex or not.

[00074] As used herein, the term "polyol" includes any compound having at least one hydroxyl group on each of two adjacent carbon atoms that are not in trans configuration relative to each other. The polyols can be linear or cyclic, substituted or unsubstituted, or mixtures

thereof, so long as the resultant complex is water soluble and pharmaceutically acceptable. Examples of such compounds include: sugars, sugar alcohols, sugar acids and uronic acids. Preferred polyols are sugars, sugar alcohols and sugar acids, including, but not limited to: mannitol, glycerin, xylitol, sorbitol and propylene glycol.

[00075] When used, the borate/polyol complex antimicrobial system (i.e., the borate and polyol together) typically comprise at least 0.05 w/v %, more typically at least 0.5 w/v % and even possibly at least 1 or even at least 1.2 w/v % of the composition and also typically comprise less than 5 w/v %, more typically less than 2.2 w/v % and even possibly less than 1.6 w/v % of the composition. The borate to polyol ratio (weight to weight ratio) in the composition is typically between 1 to 1 and 1 to 10 and more typically is between 1 to 2 and 1 to 4 (e.g., about 1 to 3).

[00076] Tyloxapol, polysorbate-80 and polyoxyl hydrogenated castor oil are preferred surfactants. Tyloxapol is a highly preferred surfactant. When used, the surfactant is typically present in a concentration that is at least 0.01 w/v %, more typically at least 0.025 w/v % and even possibly at least 0.1 w/v % of the composition and also typically is less than 5 w/v %, more typically less than 2.0 w/v % and even possibly less than 1.0 w/v % of the composition.

[00077] The compositions of the present invention that are to be used for topical applications are typically formulated so as to be compatible with the eye. The ophthalmic compositions intended for direct application to the eye will be formulated so as to have a pH and tonicity that are compatible with the eye. The compositions will typically have a pH in the range of 4 to 9, preferably 5.5 to 8.5, and most preferably 5.5 to 8.0. Particularly desired pH ranges are 6.0 to 7.8 and more specifically 6.4 to 7.6. The compositions will have an osmolality of 200 to 400 or 450 milliosmoles per kilogram (mOsm/kg), more preferably 240 to 360 mOsm/kg.

[00078] Preferred compositions of the present invention are multi-dose ophthalmic compositions, for example, where the composition is in an eye dropper and can be administered as one or more drops once, twice, thrice or more times per day, topically to the eye. In that case, the compositions preferably have sufficient antimicrobial activity to allow the compositions to satisfy the USP preservative efficacy requirements, as well as other preservative efficacy standards for aqueous pharmaceutical compositions.

[00079] The preservative efficacy standards for multi-dose ophthalmic solutions in the U.S. and other countries/regions are set forth in the following table:

Preservative
Efficacy Test
("PET") Criteria
(Log Order
Reduction of
Microbial
Inoculum Over
Time)

	Bacteria	Fungi
USP 27	A reduction of 1 log (90%), by day 7; 3 logs (99.9%) by day 14; and no increase after day 14	The compositions must demonstrate over the entire test period, which means no increases of 0.5 logs or greater, relative to the initial inoculum.
Japan	3 logs by 14 days; and no increase from day 14 through day 28.	No increase from initial count at 14 and 28 days
Ph. Eur. A ¹	A reduction of 2 logs	A reduction of 2 logs (99%) by 7 days,

	(99%) by 6 hours; 3 logs by 24 hours; and no recovery after 28 days	and no increase thereafter
Ph. Eur. B	A reduction of 1 log at 24 hours; 3 logs by day 7; and no increase thereafter	A reduction of 1 log (90%) by day 14, and no increase thereafter
FDA/ISO 14730	A reduction of 3 logs from initial challenge at day 14; and a reduction of 3 logs from rechallenge	No increase higher than the initial value at day 14, and no increase higher than the day 14 rechallenge count through day 28.

[00080] There are two preservative efficacy standards in the European Pharmacopoeia “A” and “B”.

[00081] The standards identified above for the USP 27 are substantially identical to the requirements set forth in prior editions of the USP, particularly USP 24, USP 25 and USP 26.

[00082] As an added advantage, these ophthalmic compositions containing TLR4 antagonist compounds of the present invention are suitable for topical applications to the eye.

[00083] The formulations described herein may also contain additional active ingredients, such as but not limited to anti-microbial agents as described above, pain reducing agents and the like.

[00084] As such, once made, the compounds and formulations described herein find use in the treatment of a variety of ocular inflammatory disorders including, but not limited to, AMD, sepsis and severe sepsis, SIRS and septic shock and the like. The methods comprise administering to a patient in need thereof an effective amount of the antimicrobial and anti-inflammatory compositions described herein such that the disease or disorder is treated. The medical use of such compounds will be for the treatment and/or management of sepsis, neonatal sepsis, septicemia, septic shock, burn and wounds, infective endocarditis, biofilm inhibition, ocular infection, ocular inflammation, ocular angiogenesis, diabetic retinopathy, retinopathy of prematurity, uveitis, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel diseases (IBD), asthma, chronic obstructive pulmonary disease, broncho pulmonary dysplasia, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and/or any disorder associated with inflammation, immunomodulation and microbial infection.

EXAMPLES

[00085] The following examples, including the experiments conducted and results achieved are provided for illustrative purposes only and are not to be construed as limiting the invention.

EXAMPLE 1

A series of compounds of present invention binds to TLR4 receptor effectively and not to TLR2 receptor:

[00086] ELISA plates were coated with human monocyte lysates (isolated from commercially available LeukoPak blood sample) followed by an array of compounds (10 μ M) as shown in Fig. 6. It was then incubated with human monocyte lysates and then probed with anti-TLR4 and anti-TLR2 antibodies. Plates were developed using anti human IgG-HRP positive control. Compounds **1-3**, binds to TLR4 receptor effectively and not to TLR2 receptor. Greater

chain length analogs showed stronger antagonism (FIG. 7A). Similarly, other analogs were assessed for TLR4 antagonist assay as shown in FIG. 7B. Briefly, 0.5 million cells were grown in RPMI with 10% FBS O/N in two 24 well plate. Next day, the media was taken out without disturbing the lower layer and different concentration of compounds were added to make total amount of 0.5 ml volume with RPMI which was incubated for 48hrs. Cells were harvested and the collected soup was analyzed using human TLR4 ELISA kit following manufacturer's instruction (Raybiotech).

EXAMPLE 2

Compounds were tested for inhibiting the production of inflammatory mediators in human monocytes:

[00087] To understand the structural requirement and limitations to probe the TLR4 binding pocket for optimal potency and efficacy, we have studied the ability of chitooligomers to inhibit LPS induced inflammation in human monocytes (FIG-8 A-B). Compounds **1-4** inhibited LPS induced cytokines TNF- α , IL-1 β and IL-6) in a statistically significant manner at 10 μ M concentration. Compound 2 and 4 (10 μ M) were found to be more potent than chitohexaose, (Compound 1) (10 μ M) in terms of percentage of inhibition of LPS mediated induction of inflammatory cytokines (LPS vs Chtx $p < 0.001$ whereas LPS vs compound **2** or **4** $p < 0.0001$). The protocol was followed as described [Panda et al, *PLoS Pathog* **2012**, 8, e1002717]. Human monocytes were stimulated with LPS along with the series of compounds (10 μ M) for 48 h. TNF- α , IL-1 β , IL-6 in culture supernatants were quantified according to the manufacturer's instruction. Similarly, other analogs were assessed for their ability to inhibit LPS induced TNF- α production in human monocytes. Compounds **12, 15, 16, 39, 40, 41, 42, 25** were found to be potent inhibitor of TNF- α at 100 μ M concentration (Fig. 8B).

EXAMPLE 3

Compounds 1, 2, and 26 inhibits LPS induced production of inflammatory mediator (TNF- α) in mouse bone marrow derived macrophages:

[00088] Bone marrow derived mouse macrophages were treated with 100 μ M of the above test compounds for 8 hours. Pro-inflammatory cytokines such as TNF- α protein level was measured by real-time RT-PCR. LPS treatment (10 ng/ml) was used as positive control (FIG. 9).

EXAMPLE 4**Compound 26 inhibits HMGB1 induced production of inflammatory mediators (TNF- α , i-NOS) and upregulate M2 biomarker CXCR4 in mouse macrophages:**

[00089] The expressions of TNF- α and iNOS were both inhibited by compound **26** in macrophages. Interestingly CXCR4, an M2 macrophage marker, was upregulated by **26**, suggesting potential effects on microphage polarization suggesting immune modulating activity. Bone derived macrophages from mouse were treated with HMGB1 for 8 hours, with or without 100 μ M of compound **26**. The mRNA levels of TNF- α , iNOS and CXCR4 were measured by real-time RT-PCR, and normalized to the expression level in control cells (FIG. 10).

EXAMPLE 5**Compounds of present invention produces anti-inflammatory cytokines IL-10:**

[00090] Interleukin 10 (IL-10) is a cytokine with potent anti-inflammatory properties that plays a central role in limiting host immune response to pathogens, thereby preventing damage to the host and maintaining normal tissue homeostasis. Dysregulation of IL-10 is associated with enhanced immunopathology in response to infection as well as increased risk for development of many autoimmune diseases. Here we evaluated the compounds of present invention in upregulating the IL-10 levels in PBMC using ELISA assay (Fig. 11). Briefly, 0.5 million cells were grown in RPMI with 10% FBS O/N in two 24 well plate. Next day, the media was taken out without disturbing the lower layer and different concentration of compounds (0, 1, 10, 100 μ M) were added to make total amount of 0.5 ml volume wit RPMI which was incubated for 48hrs. Cells were harvested and the collected soup was analyzed using ELISA kit following manufacturer's instruction (Raybiotech).

EXAMPLE 6**Chitohexaose (Compound 1) protected mouse from lethal gram negative sepsis against *E. Coli*:**

[00091] In an in vivo mice model, chitohexaose (Compound **1**) protected mouse from lethal gram negative sepsis against *E. Coli*. Previously reported bacterial sepsis model [Roger etal, Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2348-52] was recruited to study the efficacy

of Compound 1 (FIG-1). Intraperitoneally 2×10^5 CFU of *E. Coli* (ATCC-25922) was injected into BALB/c mice with and without Compound 1 (250 μ g/ animal). *E. Coli* mediated sepsis induced mortality whereas simultaneous treatment of mice with Compound 1 protected (40%) from sepsis induced death. The above result explained that bacteria induced sepsis and mortality is inhibited and delayed for a certain period of time which may provide a window for therapy.

EXAMPLE 7

Compound 4, 15 and 25 protected mice from CLP induced polymicrobial infection infection and sepsis:

[00092] To prove the concept and demonstrate the feasibility, we have tested compound 4 in mouse model of CLP. The CLP model consists of perforation of the cecum allowing the release of fecal material into the peritoneal cavity to generate an exacerbated immune response induced by polymicrobial infection. This model fulfills the human condition that is clinically relevant. Previously reported CLP sepsis protocol (Toscano et al, Journal of Visualized Experiments: 2011, (51), 2860] was recruited to study the efficacy of compound 4. Compound 4 (10mg/kg) was injected intravenously into C57BL/6 mice (Jackson Laboratories, 10-12 weeks, N = 15) into CLP group and CLP plus saline (0.5%) and antibiotics (primaxin, 5mg/kg) after 16, 40 h post-surgery. As a result, CLP mediated sepsis induced organ dysfunction and death whereas simultaneous treatment of mice with compound 4 protected (~93%) mice from sepsis induced death (14/15) as shown in Fig. 2. We have also demonstrated that in combination with the standard point of care anti-biotics primaxin (5mg/kg), compound 4 protected (~93%) mice from sepsis induced death (14/15) and simultaneously delayed the clinical symptoms such as body temperature lowering, shivering, huddling, loss of appetite, decreased movement, higher heart and respiratory rate.

[00093] Compound 25 (10 mg/kg) and Compound 15 (5.0 mg/kg) also protected (~60%) mice from sepsis induced death as shown in Fig. 5. We have also demonstrated that in combination with the standard point of care anti-biotics primaxin (5mg/kg), both the compounds protected (~60%) mice from sepsis induced death and simultaneously delayed the clinical symptoms such as body temperature lowering, shivering, huddling, loss of appetite, decreased movement, higher heart and respiratory rate.

EXAMPLE 8

Histopathology of organ tissues post-CLP mice

[00094] Hematoxylin Eosin (H/E) staining of different organs of Sham, CLP and compound 4 treated mice were done. Briefly, after tissues were collected they were fixed in 10% buffered neutral formalin, processed, embedded in paraffin and sectioned at 4 μ for routine hematoxylin-eosin staining. CLP mice showed micro thrombi and congestion in the heart, lungs, liver, kidney and brain, increased germinal centers size in spleen, necrosis of villi in gut and loss of testicular epithelium. On treatment with compound 4, all these changes were reversed to a major extent and tissues resembled to sham group (Fig. 3).

EXAMPLE 9

Biomarker study of the post-CLP serum:

[00095] The plasma collected from tail vein 48h post-surgery were stored at -30°C and were analyzed for TNF- α , IL-6, and IL-1 β levels for the Sham, CLP, CLP+compound 4, CLP + primaxin, CLP + primaxin + compound 4 and control (saline injected) groups. Compound 4 alone or in combination with antibiotics primaxin decreased the level of TNF- α , IL-1 β and IL-6 statistically significant (n = 4, p <0.0005) in compared to CLP group of mice (Fig. 4). Briefly commercially available ELISA Kit was used to estimate the above cytokines by a sandwich ELISA method. The ELISA plates were coated with capture antibodies followed by incubation with test samples and appropriate standards. Then it was probed with biotin labeled secondary antibodies and avidin-peroxidase. Color was developed using TMB and optical density (OD) was recorded.

EXAMPLE 10

Compounds of present invention have broad-spectrum antimicrobial activity:

[00096] The compounds were screened against selected gram negativee (*E. Coli*, *P. Aeruginosa*, *A. Baumannii*, *K. Pneumonia*), gram positive (*MRSA*) as well as fungus (*C. Albicans*) mostly found in burn and septic wounds. Most of them showed antimicrobial activity with MIC₉₀ of 50-200 mg/L (Fig.13). All prepared compounds have been evaluated in a Minimum Inhibitory Concentrations (MIC) assay with both test and control articles in accordance with guidelines of the Clinical Laboratory Standards Institute (CLSI) for broth microdilution susceptibility testing. Briefly, test and control compounds have been dissolved in DMSO, diluted to proper concentrations and added to 96-well microdilution trays. Brain Heart

Infusion Broth (BHI) was used for studies with bacterial strains such as *S. aureus*, *E. coli*, *P. Aeruginosa*, *K. pneumoniae*, *A. baumannii* and *Candida albicans*. Compounds were diluted serially from 200 µg/ml to 0.0625 µg/ml and plated in 96 well plates, and inoculated with approximately 1×10^5 CFU of each organism. The MIC endpoint was determined for each compound after 24 hrs as the lowest concentration of test or control compound which completely inhibits growth of the organism in microdilution.

EXAMPLE 11

Compounds of present invention inhibited biofilm formation:

[00097] Based on the *in vitro* antimicrobial MIC data, we have selected three compounds **1**, **12** and **15** for further study against *MRSA*. All three compounds demonstrated better activity against *MRSA* and *MSSA* strains compared to colistin (standard of care antibiotic) which was used as positive control (FIG. 14). Further we studied their biofilm inhibition and eradication activities against biofilm cells as described previously [Ceri et al, *Journal of Clinical Microbiology* **1999**, 37, 1771-1776]. The minimum biofilm eradication concentrations (MBIC) of compound **15** were superior to colistin for *MRSA*. Thus, these compounds with activities against *S. Aureus* biofilms will have significant impact on controlling recalcitrant biofilm-mediated endovascular infections [Li et al, *J Infect Dis.* 2016 Nov 1;214(9):1421-1429; Archer et al, *Virulence* 2011, 2, 445-459]. Briefly, we used Calgary Biofilm Device (CBD) technology for the biofilm susceptibilities to compounds. The CBD produces 96 equivalent biofilms for the assay of antibiotic susceptibilities by the standard 96-well technology. Susceptibility to a standard group of compounds and antibiotics was determined for National Committee for Clinical Laboratory Standards (NCCLS) as described previously.

EXAMPLE 12

The broad-spectrum antimicrobial activity of the compounds of present invention is via disruption of cell membrane:

[00098] The effects of the AVR compounds on exponentially growing *MRSA* and membrane integrity were evaluated. *MRSA* re-suspended in phosphate-buffered saline was exposed to antibiotics as well as AVR compounds **1**, **12** and **15** at their MIC value in brain heart infusion broth for 30 min and 1 hour before measuring the absorbance of leaked cellular material detected at an optical density of 260 nm in the culture filtrate (FIG. 15).

EXAMPLE 13**Compounds of present invention do not bind to the plasma serum protein.**

[00099] One of the major difficulty in designing systemic, oral or topical drug candidate is their poor plasma/tissue bioavailability due to binding of the drug to the plasma serum protein. So, we have studied the effect of serum on compounds activities by microdilution MICs in DMEM containing 10% bovine serum (GIBCO, MA) [Hurdle et al, . Journal of Antimicrobial Chemotherapy 2008, 62, 1037-1045]. The results showed (FIG.16) that all compounds were active against *MRSA* and didn't bind to the serum protein suggesting them to have good bioavailability in the target tissue.

EXAMPLE 14**Compounds of present invention are not toxic to fibroblast cells:**

[000100] Cytotoxicity and therapeutic index were also evaluated by exposing to MEF mouse fibroblast cell lines (ATCC, Manassas, VA) to antibiotic colistin and AVR compounds for 24 h, followed by an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Thermo Fischer, MA] assay as described previously. The cytotoxicity for all the AVR compounds in MEF mouse fibroblast cell line is shown in FIG. 17, indicating that AVR compounds selectively inhibit the growth of *MRSA* without compromising the growth of fibroblast cells which are critical in wound healing process.

EXAMPLE 15**Compounds 1 and 2 decreased VEGF production in ARPE-19 cell:**

[000101] Central to photoreceptor survival and function, the RPE is the major source of the angiogenic factor VEGF and therefore plays a central role in the modulation and progression of choroidal neovascularization [Spilisbury et al, The American Journal of Pathology 2000, 157, 135-144; Betts et al, ISRN Ophthalmology 2011, 2011, 184295] leading to AMD. As part of our preliminary result to evaluate if compounds 1 and 2 can inhibit the HMGB1 (an endogenous ligand for TLR4) induced VEGF production in ARPE-19 cells. Fig. 12 showed that compounds 1 and 2 (50 µg/mL) effectively reduced the HMGB1 induced VEGF production in ARPE-19 cells in a statistically significant manner ($p < 0.01$). 2×10^5 ARPE-19 cells were seeded in 24 well plate for 24 h in full medium containing 10% serum following which they were maintained for additional 24 h with serum free medium. Cells were treated with 0µg/mL (medium) or 100ng/mL

of HMGB1 along with or without of 50µg/mL of test compounds for 24 h. Supernatant was collected and assayed using human VEGF ELISA kit from Peprotech according to manufacturer's instructions. RPE cells are located adjacent to choroidal capillaries and other major ocular vasculatures. Thus these finding suggests that compounds **1** and **2** may have a significant effect on the inhibition of angiogenesis (via inhibiting TLR4 and decreasing VEGF) of choroidal as well as retinal capillaries, which contribute to the development of AMD and retinopathy.

EXAMPLE 16

Compound 2 decreased the choroidal neovascularization ~60% as compared to the positive control in a laser induced CNV mouse model for wet AMD:

[000102] To demonstrate the in vivo angiostatic effects of the AVR compounds, we have tested the compounds in mouse model of laser-induced CNV (Fig. 5). Laser CNV was induced in C57BL/6 (10-12 weeks) mice using an Iridex Oculight GL 532nm diode laser (Mountain View, CA) connected to the Micron IV fundus imaging system using a laser injector (Phoenix Research Laboratories, Pleasanton, CA). The parameters used to reproducibly obtain successful laser spots (as confirmed by a gas bubble formation indicating rupture of Bruch membrane) were: 350 mW, 75 msec, and 50 µm spot size. Four laser spots were applied; 2-3 disc diameters from the optic nerve. Mice were treated with either PBS (negative control), Compound **1**, **2**, and **26** or a positive control (anti-VEGF antibody) on days 2, 4 and 6 after laser (n = 4-6 mice/group). Compounds **1**, **2**, **26** and BSS (vehicle) were administered by IP injection once daily, and was started one day before laser and continued for 10 days after laser. By the end of the experiment, mouse eyes were examined by fundus fluorescein angiography and/or optical coherence tomography (OCT) to visualize the CNV lesions. Afterwards animals were sacrificed and RPE/choroid/sclera flat mounts were prepared and stained with both FITC-conjugated isolectin B4 and anti-ICAM-2 antibody to quantitatively measure the size of CNV. We have performed two experiments to test the effects of **1**, **2**, **26** on laser-induced CNV. As shown in Fig. 5, 200 µg daily i.p. injection of compound **2** was able to reduce the average size of CNV lesions to about 60% of those in control mice treated with vehicle only (balanced salt buffer) and comparable to the positive control.

EXAMPLE-17

Synthesis of compound 11:

[000103] To chitotriose (10mg, 0.015 mmol) in 5 mL of methanol, a methanolic solution of 4-carboxy-TEMPO (4.5 mg, 0.026 mmol) was added. To this a methanolic solution of DCC (4.66 mg, 0.026 mmol) and cat DMAP was added and stirred at room temperature for 48 h, chilled at 2°C for 12h. Ether was added to precipitate white solid, filtered and dried to provide 4.0 mg of white powder. LC/MS = 684 (M^+); ^1H NMR (DMSO- D_6 , 500MHz): δ 1.15 (s, 12H), 1.35-1.55 (m, 4H), 1.97-2.05 (bs, 10H), 2.43 (m, 1H), 2.80-3.23 (m, 4H), 3.25-3.66 (m, 11H), 4.07 (s, 2H), 4.41 (s, 2H), 4.65 (s, 2H), 5.18 (d, 1H), 5.52 (bs, 2H), 8.15 (d, 1H, NH).

Synthesis of compound 30:

[000104] To a stirred suspension of D-glucosamine **29** (100 g, 0.55 mol) in EtOH (500 mL), NaOEt (30 g, 0.55 mol) was added. After 10 minutes, the mixture was treated with dimethylmaleic anhydride (0.5 eq) and stirred for 20 minute. Triethylamine (65.2 mL, 0.465 mol) was added and the reaction mixture was again treated with remaining dimethylmaleic anhydride (0.5 eq). The reaction mixture was warmed to 60°C with stirring for 2h, EtOH was evaporated and dried. The residue was treated with pyridine, acetic anhydride and stirred at room temp for 20h. The reaction was monitored by TLC, the solvent was evaporated and the residue poured in to ice, extracted with chloroform (3 x 1 L), washed with aqueous hydrochloric acid (3%) 1L, saturated sodium bicarbonate solution (1 L), distilled water (1L), dried with anhydrous sodium sulfate. The residue was purified by silica gel chromatography using EtOAc (20-30%) in pet-ether as eluent to get compound **30** (80 g, ~37%). ^1H NMR (400 MHz, CDCl_3) : δ 1.91 (3H, s), 1.94 (6H, s), 2.01 (s, 3H), 2.03 (s, 3H), 2.09 (s, 3H), 3.92-3.96 (m, 1H), 4.0-4.12 (dd, 1H), 4.18-4.23 (dd, 1H), 4.30-4.33 (dd, 1H, $J = 4.4\text{Hz}$), 5.14 (t, 1H, $J = 9.2\text{ Hz}$), 5.69 (t, 1H, $J = 9.2\text{ Hz}$), 6.34 (d, 1H, $J = 8.8\text{ Hz}$).

Synthesis of compound 31:

[000105] To a solution of **30** (100 g, 0.219 mol) in DMF, slowly added hydrazine hydrate (12 ml, 0.219 mol) at 23°C, stirred same temp for 5-6h, and monitored by TLC. The reaction mixture was diluted with ethyl acetate (2 L) and washed with water (3 x 1 L), brine (1 L) and dried over Na_2SO_4 and evaporated to get compound **31** (65 g, ~71%). ^1H NMR (400 MHz, CDCl_3) : δ 1.85 (s, 3H), 1.90 (s, 6H), 1.98 (s, 3H), 2.05 (s, 3H), 3.79-3.84 (m, 1H), 3.95-4.06

(dd, 1H), 4.10-4.13 (dd, 1H), 4.20-4.24 (dd, 1H), 5.06 (t, 1H, J = 9.6 Hz), 5.42 (d, 1H, J = 8.4 Hz), 5.60 (t, 1H, J = 9.6 Hz).

Synthesis of compound 32:

[000106] To a stirred solution of compound **31** (35 g, 0.084 mol) and imidazole (14.4 g, 0.211 mol) in DCM, was added TBDMSCl (15.2 g, 0.101 mol) portion wise at 23°C and stirred at same temp for 16 h, monitored by TLC, diluted with DCM (1 L), washed with water (2 x 1 L), brine (500 mL), dried over Na₂SO₄ and concentrated to get crude. The residue was purified by silica gel chromatography using EtOAc (15-20%) in pet-ether as eluent to afford compound **32** (27 g, ~61%). ¹H NMR (400 MHz, CDCl₃) : δ 0.01 (s, 3H), 0.05 (s, 3H), 0.76 (s, 9H), 1.91 (s, 3H), 1.93 (s, 6H), 2.01 (s, 3H), 2.07 (s, 3H), 3.80-3.83 (m, 1H), 3.98-4.03 (dd, 1H), 4.10-4.14 (dd, 1H), 4.20-4.24 (dd, 1H), 5.05 (t, 1H, J = 9.6 Hz), 5.36 (d, 1H, J = 8.4 Hz), 5.66 (t, 1H, J = 9.6 Hz).

Synthesis of compound 33:

[000107] To a stirred solution of compound **32** (27 g, 0.051 mol) in MeOH (100 mL), was added NaOMe (2.76 g, 0.052 mol) portion wise at 23°C and stirred at same temp for 3-4 h. The reaction was monitored by TLC, MeOH was concentrated under reduced pressure and diluted with 50 mL water, pH was adjusted to 6.5-7.0, the solid was filtered and dried to get pure compound **33** (16 g, ~77%). ¹H NMR (400 MHz, CDCl₃) : δ 0.03 (s, 3H), 0.05 (s, 3H), 0.76 (s, 9H), 1.94 (s, 6H), 3.45-3.47 (m, 1H), 3.57-3.61 (m, 1H), 3.77-3.90 (m, 3H), 4.21 (t, 1H, J = 8.0 Hz), 5.23 (d, 1H, J = 8.0 Hz).

Synthesis of compound 34:

[000108] A suspension of compound **33** (30 g, 0.074 mol) and dibutyltin oxide (37.25 g, 0.149 mol) in toluene (400 mL) was heated under reflux for 12 h, tetrabutylammonium iodide (55.2 g, 0.149 mol) and benzyl bromide (25.5 g, 0.149 mol) were added and the mixture was gently refluxed for 3 h, the reaction mixture was cooled, concentrated to get crude. The residue was purified by silica gel chromatography by using 15-20% EtOAc in pet-ether to yield **34** (25 g, ~60%). ¹H NMR (400 MHz, CDCl₃) : δ 0.06 (s, 3H), 0.02 (s, 3H), 0.73 (s, 9H), 1.83-1.93 (bs, 6H), 3.56-3.61 (m, 1H), 3.72-3.80 (m, 2H), 3.86-3.89 (dd, 1H), 4.09-4.14 (dd, 1H), 4.53 (d, 1H, J = 12 Hz), 4.56-4.63 (dd, 2H), 4.69-4.76 (dd, 2H), 5.16 (t, 1H, J = 8.0 Hz), 7.15-7.24 (m, 5H), 7.33-7.37 (m, 5H).

Synthesis of compound 35:

[000109] To a mixture of compound **31** (5 g, 0.012 mol) and CCl_3CN (2.06 g, 0.014 mol) in dry CH_2Cl_2 was added DBU (0.37 g, 0.002 mol) and stirred at RT for 15-16h. The reaction mixture was concentrated to get crude. The crude was purified by silica gel chromatography by using EtOAc (25-35%) in pet-ether to yield **35** (3.8 g, 55%). ^1H NMR (400 MHz, CDCl_3) : δ 1.91 (s, 3H), 1.93 (s, 6H), 2.01 (s, 3H), 2.07 (s, 3H), 3.93-4.01 (m, 1H), 3.98-4.03 (dd, 1H), 4.33-4.40 (m, 2H), 5.20 (t, 1H, $J = 9.2$ Hz), 5.73 (t, 1H, $J = 9.2$ Hz), 6.45 (d, 1H, $J = 9.2$ Hz), 8.67 (s, 1H).

Synthesis of compound 36:

[000110] A mixture of **35** (4 g, 0.007 mol) and **34** (3.3 g, 0.0057 mol) is taken in oven dried round bottom flask containing activated molecular sieves powder (4A°). Then the RB was back filled with argon twice and added dry DCM (10 mL), stirred at 23°C for 2 h. Then resulting reaction mixture was cooled to -10°C and added 0.1M solution of TfOH in DCM and further stirred for 16 h. The reaction mixture was concentrated under reduced pressure to get crude mixture which was purified by silica gel chromatography by using EtOAc (25-35%) in pet-ether to yield **36** (2 g, 30%). ^1H NMR (400 MHz, CDCl_3) : δ -0.005 (s, 3H), -0.11 (s, 3H), 0.71 (s, 9H), 1.76 (bs, 6H), 1.90 (s, 3H), 1.95 (bs, 6H), 1.98 (s, 3H), 3.36-3.44 (m, 3H), 3.48-3.55 (m, 3H), 3.80-3.83 (m, 2H), 3.90-3.93 (dd, 1H), 4.04-4.12 (m, 3H), 4.14-4.20 (dd, 1H), 4.42 (d, 1H, $J = 12.4$ Hz), 4.57-4.64 (dd, 2H), 4.81 (d, 1H, $J = 12.4$ Hz), 5.03-5.08 (m, 2H), 5.36 (d, 1H, $J = 8.4\text{Hz}$), 5.61 (t, 1H, $J = 9.2$ Hz), 7.13-7.19 (m, 5H), 7.33-7.39 (m, 5H).

Synthesis of compound 37:

[000111] To a solution of compound **36** (5.5 g, 0.0056 mol) in dry THF (50 mL) was added AcOH (0.36 mL, 0.0063 mol) and cooled to -5°C . Then added 1 M TBAF (6.3 mL, 0.0063 mol) soln in THF at -5°C stirred at room temperature for 16h. After completion of the reaction, reaction mixture was quenched with sat NaCl solution, extracted with DCM and concentrated under reduced pressure to obtain crude compound **37** (3 g, crude) which was used further reaction without purification. ^1H NMR (400 MHz, CDCl_3) : δ 1.76 (s, 6H), 1.89 (s, 3H), 1.95 (bs, 6H), 1.98 (s, 3H), 3.38-3.55 (m, 3H), 3.62-3.66 (m, 1H), 3.76-3.80 (m, 1H), 3.90-3.94 (m, 1H), 4.06-4.22 (m, 6H), 4.14-4.20 (dd, 1H), 4.40 (d, 1H, $J = 12.8$ Hz), 4.57-4.64 (dd, 2H), 4.85 (d, 1H, $J = 12.8$ Hz), 5.01-5.07 (m, 2H), 5.33 (d, 1H, $J = 8.4\text{Hz}$), 5.55-5.63 (t, 1H, $J = 9.2$ Hz), 7.11-7.20 (m, 5H), 7.29-7.42 (m, 5H).

Synthesis of compound 38:

[000112] To a mixture of compound **37** (4 g, 0.0045 mol) and CCl_3CN (0.54 mL, 0.0054 mol) in dry CH_2Cl_2 was added DBU (0.13 mL, 0.0009 mol) stirred at RT for 15-16h. The reaction mixture was concentrated to get crude. The crude was purified by silica gel chromatography by using EtOAc (25-35%) in pet-ether to yield **38** (1 g, 20 %).

[000113]

Synthesis of compounds 39-42:

[000114] A mixture of **38** (1 g, 0.89 mmol) and R-OH (0.7 eq) is taken in oven dried round bottom flask containing activated molecular sieves powder (4 A°) then RB was back filled with argon twice and added dry DCM (20 mL), stirred at rt for 2 h. Then resulting reaction mixture was cooled to -10°C and added 0.1M solution of TfOH (1.3 mL, 0.13 mmol) in DCM and further stirred for 16 h. The reaction mixture was concentrated under reduced pressure to get crude mixture. The crude was purified by silica gel chromatography by using EtOAc (25-35%) in pet-ether to yield compounds **39-42** (~ 40-45%).

[000115] **Compound-39:** $^1\text{H NMR}$ (400 MHz, CDCl_3) : δ 1.76 (s, 6H), 1.89 (s, 3H), 1.95 (bs, 6H), 1.98 (s, 3H), 3.49-3.51 (m, 2H), 3.64-3.71 (m, 2H), 3.94-3.96 (m, 1H), 4.15-4.19 (m, 6H), 4.40 (m, 1H), 4.56-4.65 (m, 2H), 4.86-4.91 (m, 1H), 5.06-5.09 (m, 1H), 5.33 (d, 1H, $J = 8.4\text{Hz}$), 5.55-5.63 (t, 1H, $J = 9.2\text{ Hz}$), 6.91 (d, 2H, $J = 8.4\text{ Hz}$), 7.12-7.21 (m, 5H), 7.29-7.42 (m, 5H), 8.06 (d, 2H, $J = 8.4\text{ Hz}$). LC/MS: $\text{M}^+ = 982$.

[000116] **Compound-40:** $^1\text{H NMR}$ (400 MHz, CDCl_3) : δ 1.21-1.48 (m, 10H), 1.76 (bs, 6H), 1.89 (s, 3H), 1.95-1.96 (s, 9H), 1.98 (s, 3H), 3.36-3.38 (m, 1H), 3.43-3.46 (m, 3H), 3.59 (d, 1H, $J = 8.4\text{ Hz}$), 3.89-3.92 (m, 2H), 4.04-4.08 (m, 4H), 4.41 (d, 1H, $J = 10.0\text{ Hz}$), 4.60 (s, 2H), 4.84 (d, 1H, $J = 10.0\text{ Hz}$), 4.93 (d, 1H, $J = 6.4\text{Hz}$), 5.04 (t, 1H, $J = 7.2\text{ Hz}$), 5.35 (d, 1H, $J = 6.4\text{Hz}$), 5.57-5.61 (t, 1H, $J = 7.2\text{ Hz}$), 7.13-7.19 (m, 5H), 7.28-7.40 (m, 5H),. LC/MS: $\text{M}^+-2 = 943$.

[000117] **Compound-41:** $^1\text{H NMR}$ (400 MHz, CDCl_3) : δ 1.21-1.35 (m, 8H), 1.45-1.62 (bs, 8H), 1.76 (bs, 6H), 1.90 (s, 3H), 1.95-2.22 (m, 12H), 3.43-3.46 (m, 4H), 3.60-3.71 (m, 1H), 3.94 (d, 1H), 4.04-4.12 (m, 4H), 4.20 (m, 1H), 4.55-4.59 (m, 1H), 4.62-4.70 (m, 2H), 4.84 (d, 1H, $J = 10.0\text{ Hz}$), 4.93 (d, 1H, $J = 6.4\text{Hz}$), 5.30 (t, 1H, $J = 7.2\text{ Hz}$), 5.35 (m, 1H), 5.61 (t, 1H, $J = 7.2\text{ Hz}$), 7.13-7.19 (m, 5H), 7.28-7.40 (m, 5H),. LC/MS: $\text{M}^+-2 = 1015$.

[000118] Compound-42: ^1H NMR (400 MHz, CDCl_3): δ 1.76 (s, 6H), 1.90 (s, 3H), 1.95 (s, 3H), 1.98 (s, 6H), 2.01 (s, 3H), 3.43-3.49 (m, 3H), 3.62-3.64 (m, 1H), 3.72 (s, 3H), 3.91-3.94 (m, 1H), 4.07-4.21 (m, 5H), 4.42 (d, 1H, $J = 12.4$ Hz), 4.59 (s, 2H), 4.85 (d, 1H, $J = 12.4$ Hz), 5.05 (t, 1H, $J = 10.8$ Hz), 5.34-5.37 (m, 2H), 5.60 (t, 1H, $J = 10.8$ Hz), 6.69 (d, 2H, $J = 9.2$ Hz), 6.77 (d, 2H, $J = 9.2$ Hz), 7.11-7.21 (m, 5H), 7.29-7.42 (m, 5H). LC/MS: $\text{M}^+ = 986$.

Synthesis of compound 15:

[000119] Compound 15 was synthesized from compound 39 (0.5 g) by removal of NDMM group using hydrazine hydrate in HCl followed by treatment with Ac_2O to introduce NHAc group. Finally removal of $-\text{OAc}$ groups by $\text{NaOCH}_3/\text{MeOH}$ at room temperature as described previously [Mohamed R. E et al, Carbohydrate research, 2001, 331, 129-142] afforded compound **15** (22 mg white solid). ^1H NMR (400 MHz, CDCl_3): δ 1.98 (s, 6H), 3.43-3.49 (m, 3H), 3.62-3.64 (m, 1H), 3.72 (s, 3H), 3.91-3.94 (m, 1H), 4.23-4.42 (m, 3H), 4.62 (m, 4H), 5.90 (d, 1H, $J = 10.8$ Hz), 6.42 (d, 1H, $J = 10.8$ Hz), 6.91 (d, 2H, $J = 8.4$ Hz), 7.12-7.21 (m, 5H), 7.29-7.42 (m, 5H), 8.06 (d, 2H, $J = 8.4$ Hz). LC/MS: $\text{M}^+ = 710$.

[000120]

Synthesis of compound-43:

[000121] To a stirred suspension of D-glucosamine **29** (200 g, 0.93 mol) in pyridine was added acetic anhydride (720 mL, 7.4 mol). The reaction mixture was warmed to 60°C with stirring for 12h (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The residue poured in to ice, extracted with chloroform (3 x 1 L), washed with aqueous hydrochloric acid (3%) 1L, saturated sodium bicarbonate solution (1 L), distilled water (1L), dried by anhydrous sodium sulfate. The crude mixture **43** was preceded to next step without further purification.

Synthesis of compound 44:

[000122] To a solution of **43** (30g, 77.09 mmol) in THF, slowly added Methyl amine in MeOH (2M, 77mL, 154.1 mmol) at RT and stirred same temp for 12 h, monitored by TLC. The reaction mixture was diluted with ethyl acetate (2 L) and washed with water (3 x 1 L), brine (1 L) and dried over Na_2SO_4 and evaporated. To get compound **44** (20 g).

Synthesis of compound-45:

[000123] A mixture of **44** (20g, 0.057 mol), CCl_3CN (11 mL, 0.114 mol), and DBU (2.5 mL, 0.0014 mol) in dry CH_2Cl_2 was stirred at RT for 15-16h. The reaction mixture was concentrated to get crude. The crude was purified by silica gel chromatography by using EtOAc (25-35%) in pet-ether to yield compound **45** (5 g). ^1H NMR (400 MHz, CDCl_3) : δ 1.91 (s, 3H), 1.93 (s, 3H), 2.01 (s, 3H), 2.07 (s, 3H), 3.93-4.01 (m, 1H), 3.98-4.03 (dd, 1H), 4.33-4.40 (m, 2H), 5.20 (t, 1H, $J = 9.2$ Hz), 5.73 (t, 1H, $J = 9.2$ Hz), 6.45 (d, 1H, $J = 9.2$ Hz), 8.67 (s, 1H).

[000124]

Synthesis of compound-24:

[000125] To a stirred suspension of **45** (2g, 5.14 mmol) and 4-OH-TEMPOL (0.7g, 4.11 mmol) in DCM with molecular sieves powder stirred for 2h at RT, Triflic acid (0.11g, 0.77 mmol) was added and stirred for 4h at RT. The RM was distilled and purified by column chromatography eluted with 5%MeOH in DCM to provide compound **24** (300mg). ^1H NMR (400 MHz, CDCl_3) : δ 1.14 (s, 12H), 1.41-1.66 (m, 4H), 1.91 (s, 3H), 1.93 (s, 3H), 2.01 (s, 3H), 2.07 (s, 3H), 4.15-4.36 (m, 4H), 5.30 (d, 1H, $J = 9.2$ Hz), 5.73 (t, 1H, $J = 9.2$ Hz), 6.45 (d, 1H, $J = 9.2$ Hz). TLC system: 10%MeOH in DCM, R_f : 0.3.

Synthesis of compound 25:

[000126] To a stirred solution of compound **24** (0.3 g, 0.79 mmol) in MeOH, was added NaOMe (0.04 g, 0.63 mmol) at RT and stirred at same temp for 3-4 h. The reaction mixture was monitored by TLC, MeOH was concentrated, neutralized with 1 M Dioxane in HCl. The RM was concentrated and purified by column chromatography with 7% MeOH in DCM as eluent to get compound **25** (50 mg). ^1H NMR (400 MHz, CDCl_3): δ 1.14 (s, 12H), 1.41-1.66 (m, 4H), 1.93 (s, 3H), 4.15-4.36 (m, 4H), 5.30 (d, 1H, $J = 9.2$ Hz), 5.73 (t, 1H, $J = 9.2$ Hz), 6.45 (d, 1H, $J = 9.2$ Hz). LC/MS: $M^+ = 374$. TLC system: 10% MeOH in DCM, R_f : 0.2.

Example-18

Topical/intravitreal formulation

[000127] The table below represents exemplary ranges for a topical or intravitreal ophthalmic composition according to the present invention:

Ingredients	w/v%
Compound 2	0.1 to 1.5
Mannitol	2.0
Sodium acetate	0.5
Acetic acid	0.02
PEG 8000	2.0
Polysorbate 80	1.0
HPMC	0.5
Sodium hydroxide/Hydrochloric acid	For adjusting pH 6.5-7.4
Water	Q.S. to 100

Example-19**Injectable Formulation**

[000128] The table below represents exemplary ranges for an intravenous (IV) composition according to the present invention: The compound of the invention is dissolved in most of the water (35° 40° C.) and the pH adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium hydroxide as appropriate. The batch is then made up to volume with water and filtered through a sterile micropore filter into a sterile 10 mL amber glass vial (type 1) and sealed with sterile closures and over seals.

Ingredients	Amount
Compound 15 , 25	5-10 mg/kg
Hydrochloric Acid Solution 0.1M or	4.0 to 7.0 (pH)
Sodium Hydroxide Solution 0.1M q.s. to pH	4.0 to 7.0 (pH)
Sterile water q.s. to	10 mL

Example-20

[000129] The tables below represents exemplary ranges for topical gel, lotion and spray compositions according to the present invention:

Gel formulation:

[000130] The table below represents exemplary ranges for gel composition according to the present invention: Disperse the Carbomer 934 uniformly in about 40 % of total amount of water. Add the ammonia solution gradually into the dispersion with agitation to form a clear gel. In a separate container dissolve the methyl paraben in polyethylene glycol and then disperse 10.0 g of compound **15** in this solution to make a homogenous suspension. Gradually add the suspension into the gel with agitation, a uniform white opaque gel will be obtained.

Ingredient	Amount
Compound 15	10.0 g
Carbomer 934	3.0 g

Propylene Glycol	40 mL
Strong ammonia solution	4.0 mL
Methyl paraben	3.0 g
Purified water, USP q. s to	1000 g

Cream or lotion formulation:

[000131] The table below represents exemplary ranges for cream or lotion composition according to the present invention: dissolve the methyl paraben in about 80% of total amount of propylene glycol. Add the poloxyl 2 cetyl ether into this solution with agitation. In a separate processing container mix the 20% of the propylene glycol, part of the purified water and 10.0 g of compound **15** to form a uniform suspension. Gradually add the suspension into the first processing container with moderate stirring until a homogenous, soft, white cream is obtained. Pass the cream through a colloid mill and bring the mass of the batch to the targeted quantity.

Ingredient	Amount
Compound 15	10.0 g
Poloxyl 2 cetyl ether	50.0 g
Propylene Glycol	50 mL
Methyl paraben	3.0 g
Purified water, USP q. s to	1000 g

Non-aerosol spray formulation:

[000132] The table below represents exemplary ranges for non-aerosol spray composition according to the present invention: 5.00g of polyoxyl 10 oleyl ether is dissolved in 188.75 g of castor oil with gentle stirring. 25.0 g of compound **15** and 25.0 g of zinc oxide were suspended to the slurry with moderate stirring followed by 1.25 g of fumed silica gel. The slurry is mixed under high shear stress until uniform and smooth and packaged in a spray bottle.

[000133] The present invention and its embodiments have been described in detail. However, the scope of the present invention is not intended to be limited to the particular embodiments of any process, manufacture, composition of matter, compounds, means, methods, and/or steps described in the specification. Various modifications, substitutions, and variations can be made to the disclosed material without departing from the spirit and/or essential characteristics of the present invention. Accordingly, one of ordinary skill in the art will readily appreciate from the disclosure that later modifications, substitutions, and/or variations performing substantially the same function or achieving substantially the same result as embodiments described herein may be utilized according to such related embodiments of the present invention. Thus, the following claims are intended to encompass within their scope modifications, substitutions, and variations to processes, manufactures, compositions of matter, compounds, means, methods, and/or steps disclosed herein.

Ingredient	Amount
Compound 15	25.0 g
Zinc oxide	25.0 g
Castor oil	188.75 g
Polyoxy 10 oleyl ether	5 g
Fumed silica	1.25

[000134] In so far as the description above and the accompanying drawings disclose any additional subject matter, the inventions are not dedicated to the public and the right to file one or more applications to claim such additional inventions is reserved.

References

- [001] Leon, Carlos G.; Tory, Rita; Jia, Jessica; Sivak, Olena; Wasan, Kishor M. a. *Pharmaceutical Research* (2008), 25(8), 1751-1761.
- [002] Savva Athina; Roger Thierry From *Frontiers in immunology* (2013), 4387, Language: English, Database: MEDLINE
- [003] Cho, Y.; Wang, J. J.; Chew, E. Y.; Ferris, F. L.; Mitchell, P.; Chan, C.-C.; Tuo, J., Toll-like Receptor Polymorphisms and Age-Related Macular Degeneration: Replication in Three Case–Control Samples. *Investigative Ophthalmology & Visual Science* **2009**, 50, (12), 5614-5618.
- [004] Higgins, G. T.; Wang, J. H.; Dockery, P.; Cleary, P. E.; Redmond, H. P., Induction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segments. *Invest Ophthalmol Vis Sci.* **2003**, 44(4):1775-82
- [005] Kaarniranta, K.; Salminen, A., Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors. *J Mol Med (Berl).* **2009**, 87(2):117-23.
- [006] Elner, S. G.; Petty, H. R.; Elner, V. M.; Yoshida, A.; Bian, Z.-M.; Yang, D.; Kindezelskii, A. L., TLR4 mediates human retinal pigment epithelial endotoxin binding and cytokine expression. *Transactions of the American Ophthalmological Society* **2005**, 103, 126-137.
- [007] Yi, H.; Patel, A. K.; Sodhi, C. P.; Hackam, D. J.; Hackam, A. S., Novel Role for the Innate Immune Receptor Toll-Like Receptor 4 (TLR4) in the Regulation of the Wnt Signaling Pathway and Photoreceptor Apoptosis. *PLoS One* **2012**, 7, (5), e36560.
- [008] He, C.; Sun, Y.; Ren, X.; Lin, Q.; Hu, X.; Huang, X.; Su, S.-B.; Liu, Y.; Liu, X., Angiogenesis mediated by toll-like receptor 4 in ischemic neural tissue. *Arterioscler Thromb Vasc Biol.* **2013**, 33(2):330-8.

- [0009] Huang, J.-D.; Amaral, J.; Lee, J. W.; Rodriguez, I. R., 7-Ketocholesterol-Induced Inflammation Signals Mostly through the TLR4 Receptor Both In Vitro and In Vivo. *PLoS One* **2014**, 9, (7), e100985.
- [0010] CN 102475714.
- [0011] CN 101732338.
- [0012] US 20020022601.
- [0013] Hadwiger, Lee A.; Klosterman, S.; Chang, M.-M.; Friel, P.; Hosick, H. L., From *Advances in Chitin Science* (1997), 2, 102-109.
- [0014] EP 183556.
- [0015] Xu, Ke; Chen, Jun-quan *Zhongguo Laonianxue Zazhi* (2012), 32(24), 5478-5480.
- [0016] Wang, Jianyun; Chen, Yuanwei; Ding, Yulong; Shi, Guoqi; Wan, Changxiu, *Applied Surface Science* (2008), 255(2), 260-262.
- [0017] Xiong, Chuannan; Wu, Haige; Wei, Peng; Pan, Ma; Tuo, Yaqin; Kusakabe, Isao; Du, Yuguang, *Carbohydrate Research* (2009), 344(15), 1975-1983.
- [0018] CN102085212.
- [0019] Opal, S. M.; Laterre, P.; Francois, B.; et al., Effect of eritoran, an antagonist of md2-tlr4, on mortality in patients with severe sepsis: The access randomized trial. *JAMA* 2013, 309, 1154-1162.
- [0020] Wong, W. L.; Su, X.; Li, X.; Cheung, C. M. G.; Klein, R.; Cheng, C.-Y.; Wong, T. Y., Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *The Lancet Global Health* 2014, 2, e106-e116.
- [0021] Harrell, S. N.; Brandon, D. H., *Retinopathy of Prematurity: The Disease Process, Classifications, Screening, Treatment, and Outcomes*. Neonatal Network 2007, 26, 371-378.
- [0022] Cho, Y.; Wang, J. J.; Chew, E. Y.; Ferris, F. L.; Mitchell, P.; Chan, C.-C.; Tuo, J., Toll-like Receptor Polymorphisms and Age-Related Macular Degeneration: Replication in Three Case-Control Samples. *Investigative Ophthalmology & Visual Science* 2009, 50, 5614-5618.


- [0023] He, C.; Sun Y Fau - Ren, X.; Ren X Fau - Lin, Q.; Lin Q Fau - Hu, X.; Hu X Fau - Huang, X.; Huang X Fau - Su, S.-B.; Su Sb Fau - Liu, Y.; Liu Y Fau - Liu, X.; Liu, X., Angiogenesis mediated by toll-like receptor 4 in ischemic neural tissue.
- [0024] Xia, W.; Liu, P.; Zhang, J.; Chen, J., Biological activities of chitosan and chitooligosaccharides. *Food Hydrocolloids* 2011, 25, 170-179.
- [0025] Mosser, D. M., The many faces of macrophage activation. *Journal of Leukocyte Biology* 2003, 73, 209-212.
- [0026] Panda, S. K.; Kumar, S.; Tupperwar, N. C.; Vaidya, T.; George, A.; Rath, S.; Bal, V.; Ravindran, B., Chitohexaose Activates Macrophages by Alternate Pathway through TLR4 and Blocks Endotoxemia. *PLoS Pathog* 2012, 8, e1002717.
- [0027] Roger, T.; Froidevaux C Fau - Le Roy, D.; Le Roy D Fau - Reymond, M. K.; Reymond Mk Fau - Chanson, A.-L.; Chanson Al Fau - Mauri, D.; Mauri D Fau - Burns, K.; Burns K Fau - Riederer, B. M.; Riederer Bm Fau - Akira, S.; Akira S Fau - Calandra, T.; Calandra, T., Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4.
- [0028] Ceri, H.; Olson, M. E.; Stremick, C.; Read, R. R.; Morck, D.; Buret, A., The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms. *Journal of Clinical Microbiology* 1999, 37, 1771-1776.
- [0029] Li, L.; Cheung, A.; Bayer, A. S.; Chen, L.; Abdelhady, W.; Kreiswirth, B. N.; Yeaman, M. R.; Xiong, Y. Q., The Global Regulon sarA Regulates beta-lactam Antibiotic Resistance In Methicillin-resistant Staphylococcus aureus (MRSA) In Vitro and In Endovascular Infections. *The Journal of infectious diseases* 2016.
- [0030] Archer, N. K.; Mazaitis, M. J.; Costerton, J. W.; Leid, J. G.; Powers, M. E.; Shirtliff, M. E., Staphylococcus aureus biofilms: Properties, regulation and roles in human disease. *Virulence* 2011, 2, 445-459.
- [0031] Hurdle, J. G.; Yendapally, R.; Sun, D.; Lee, R. E., Evaluation of Analogs of Reutericyclin as Prospective Candidates for Treatment of Staphylococcal Skin Infections. *Antimicrobial Agents and Chemotherapy* 2009, 53, 4028-4031.

- [0032] Hurdle, J. G.; Lee, R. B.; Budha, N. R.; Carson, E. I.; Qi, J.; Scherman, M. S.; Cho, S. H.; McNeil, M. R.; Lenaerts, A. J.; Franzblau, S. G.; Meibohm, B.; Lee, R. E., A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. *Journal of Antimicrobial Chemotherapy* 2008, 62, 1037-1045.
- [0033] Spilsbury, K.; Garrett, K. L.; Shen, W.-Y.; Constable, I. J.; Rakoczy, P. E., Overexpression of Vascular Endothelial Growth Factor (VEGF) in the Retinal Pigment Epithelium Leads to the Development of Choroidal Neovascularization. *The American Journal of Pathology* 2000, 157, 135-144.
- [0034] Betts, B. S.; Parvathaneni, K.; Yendluri, B. B.; Grigsby, J.; Tsin, A. T. C., Ginsenoside-Rb1 Induces ARPE-19 Proliferation and Reduces VEGF Release. *ISRN Ophthalmology* 2011, 2011, 184295.

CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising a compound according to Formula (VI), or a pharmaceutically acceptable salt thereof:



Formula-VI

where:

$n = 0-1$


R = benzyl, substituted benzyl

R₁ = COCH₃, N-dimethylmaleimide

R₃ = cyclohexyl, p-nitro phenyl, piperidine, nitroxy, piperidine-N-hydroxyl, p-methoxy phenyl.

2. The composition of claim 1, wherein the composition is formulated a sterile, injectable aqueous or oleaginous suspension.
3. The composition of claim 1, wherein the composition is formulated as a sterile topical gel, ointment or aqueous spray.
4. The composition of claim 1, further comprising an anti-inflammatory agent.
5. The composition of claim 1, further comprising an anti-microbial agent.
6. A method of treating sepsis, septic shock, septicemia, burn or wound infection, which comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound according to Formula (VI), or a pharmaceutically acceptable salt thereof, whereby said subject is treated.
7. The method according to claim 6, wherein said administering comprises administering said pharmaceutical composition comprising about 5.0 mg to about 100 mg of a compound according to Formula (VI), or a pharmaceutically acceptable salt thereof to a patient in need thereof, whereby said patient is treated.

8. The method according to claim 6, wherein said administering comprises administering said pharmaceutical composition comprising about 10.0 mg to about 1000 mg of a compound according to Formula (VI), or a pharmaceutically acceptable salt thereof to a patient in need thereof, whereby said patient is treated..
9. A pharmaceutical composition comprising a compound according to Formula (V), or a pharmaceutically acceptable salt thereof:



Formula V

where:

$n = 0-5$


$R = H, C(O)CH_3, C(O)$ -piperidine nitroso, $C(O)$ -piperidine N-hydroxyl

$R_1 =$ alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl, piperidine nitroso, piperidine N-hydroxyl.

10. The composition of claim 9, wherein the composition is formulated a sterile, injectable aqueous or oleaginous suspension.
11. The composition of claim 9, wherein the composition is formulated as a sterile topical gel, ointment or aqueous spray.
12. The composition of claim 9, further comprising an anti-inflammatory agent.
13. The composition of claim 9, further comprising an anti-microbial agent.
14. A method of treating sepsis, septic shock, septicemia, burn or wound infection, which comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound according to Formula (V), or a pharmaceutically acceptable salt thereof.
15. The method according to claim 14, wherein said administering comprises administering said pharmaceutical composition comprising about 5.0 mg to about 100 mg of a

compound according to Formula (V), or a pharmaceutically acceptable salt thereof to a patient in need thereof, whereby said patient is treated.

16. The method according to claim 14, wherein said administering comprises administering said pharmaceutical composition comprising about 10.0 mg to about 1000 mg of a compound according to Formula (V), or a pharmaceutically acceptable salt thereof to a patient in need thereof, whereby said patient is treated.
17. A composition comprising an effective amount of a compound according to Formula (II), or a pharmaceutically acceptable salt thereof:



Formula II

where:

$$n = 5-7$$

and a pharmaceutically acceptable vehicle, wherein said vehicle comprises PLA or PLGA microparticle.

18. The composition of claim 17, wherein the composition is formulated a sterile, injectable aqueous or oleaginous suspension.
19. The composition of claim 17, wherein the composition is formulated as a sterile topical ocular solution.
20. The composition of claim 17, further comprising an anti-inflammatory agent.
21. The composition of claim 17, further comprising an anti-microbial agent.
22. A method of treating ocular angiogenesis, ocular inflammation which comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound according to Formula (II), or a pharmaceutically acceptable salt thereof, whereby said subject is treated.
23. The method according to claim 22, wherein said administering comprises administering said pharmaceutical composition comprising about 5.0 mg to about 100 mg of a

compound according to Formula (II), or a pharmaceutically acceptable salt thereof to a patient in need thereof, whereby said patient is treated.

24. The method according to claim 22, wherein said administering comprises administering said pharmaceutical composition comprising about 10.0 mg to about 1000 mg of a compound according to Formula (II), or a pharmaceutically acceptable salt thereof to a patient in need thereof, whereby said patient is treated.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7A





Fig. 7B



* P < 0.05 compared to only cell lysate (Unpaired t test)

Fig. 8A




Fig. 8B




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13

Compound	<i>E. Coli</i>	<i>P.Aeru ginosa</i>	<i>K.Pneumo niae</i>	<i>A. Baumannii</i>	<i>S. Aureus</i>	<i>C. albicans</i>
	MIC ₉₀ mg/L	MIC ₉₀ mg/L	MIC ₉₀ mg/L	MIC ₉₀ mg/L	MIC ₉₀ mg/L	MIC ₉₀ mg/L
Colistin	1	4	128	4	>128	NA
Fluconazole	NA	NA	NA	NA	NA	>128
13	200	200	200	200	>200	200
14	200	200	200	200	>200	200

12	50	200	100	100	200	200
15	50	100	50	50	200	100
27	100	100	200	200	200	200
4	200	200	200	200	200	100
1	200	100	100	100	100	50
2	Resistant	>200	Resistant	Resistant	Resistant	Resistant

Fig. 14

Compound	<i>MIC</i> ₉₀		MBEC ₉₀		MBIC ₉₀	
	MRSA	MSSA	MRSA	MSSA	MRSA	MSSA
Colistin	>128	128	128	32	>128	100
1	100	100	200	200	200	100
12	100	100	200	200	200	100
15	200	50	200	100	100	50

Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig. 19





Fig. 20



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US17/24908

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C07H 5/06, 5/08, 13/04 (2017.01)

CPC - C07H 5/06, 5/08, 13/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2011/0044901 A1 (SEED, MP et al.) 24 February 2011; paragraphs [0058], [0083]-[0085], [0092]-[0093], [0175], [0179], [0221], [0223], [0251], [0258], [0278], [0286]-[0287], [0291]	1-8
Y	WO 2014/186358 A2 (DIGIANDOMENICO, A et al.) 20 November 2014; paragraph [0009]	1-8
Y	US 2015/0225488 A1 (THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL) 13 August 2015; paragraph [0179]	4-5

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 May 2017 (30.05.2017)

Date of mailing of the international search report

17 AUG 2017

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US17/24908

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

-Please See Extra Sheet Below-

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-8

- Remark on Protest**
- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
 - The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
 - No protest accompanied the payment of additional search fees.

-Continued from Box III: Observations where unity of invention is lacking-

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I: Claims 1-8 are directed toward a method of treating sepsis, septic shock, septicemia, burn or wound infection, which comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound according to Formula (VI).

Group II: Claims 9-16 are directed toward a method of treating sepsis, septic shock, septicemia, burn or wound infection, which comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound according to Formula (V).

Group III: Claims 17-24 are directed toward a method of treating sepsis, septic shock, septicemia, burn or wound infection, which comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound according to Formula (II).

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical features of Group I include a compound of Formula (VI) wherein R is benzyl or substituted benzyl, which are not present in Groups II-III; the special technical features of Group II include a compound of Formula (V) wherein R is H, C(O)CH₃, C(O)-piperidine nitroxy, or C(O)-piperidine N-hydroxyl, which are not present in Groups I and III; and the special technical features of Group III include a compound of Formula (II) wherein each 2-position is OH and n is 5-7, which are not present in Groups I-II.

The common technical features of Groups I-III are a polysaccharide compound of two or more repeating sugar units joined by an oxygen atom wherein each ring comprises an optionally substituted amine group.

These common technical features are disclosed by US 2011/0044901 A1 to Seed, et al. (hereinafter 'Seed') in view of WO 2014/186358 A2 to Digiandomenico, et al. (hereinafter 'Digiandomenico'). Seed discloses a monosaccharide compound (n is 1) wherein two hydroxyl groups are replaced with -Ra-N(Rb)-CO-Rb (two substituted amine groups); paragraphs [0058], [0083]-[0085], [0092]-[0093], [0175], [0179]), but Seed does not disclose wherein the compound comprises an oxygen atom linking the sugar moieties. However, Digiandomenico discloses wherein the compound comprises an oxygen atom linking the sugar moieties. It would have been obvious to a person of ordinary skill in the art, at the time of the invention, to have modified the composition, as previously disclosed by Seed, in order to have provided wherein the compound comprises an oxygen atom linking the sugar moieties, as previously disclosed by Digiandomenico, for providing compounds and pharmaceutical compositions useful in the treatment of bacterial infections, such as *Pseudomonas aeruginosa* (Digiandomenico; paragraph [0003]), that can result in serious medical conditions, such as sepsis and septic shock (Seed; paragraphs [0251]).

Since the common technical features are previously disclosed by Seed and Digiandomenico, these common features are not special and so Groups I-III lack unity.